logo
Plus   Neg
Share
Email

Merck Says Phase 3 KEYTRUDA Trial Meets Primary Endpoint

Merck (MRK) Monday said its KEYTRUDA anti-PD-1 therapy for surgically resected high-risk melanoma met the primary endpoint of recurrence-free survival. The company, known as MSD outside the US, said phase 3 randomized, double-blind EORTC1325/KEYNOTE-054 trial resulted in significantly longer recurrence-free survival than placebo. The study will continue in order to evaluate other key endpoints, including overall survival.

Merck plans to present the results at an upcoming medical meeting.
In total, the study enrolled 1,019 patients who were randomly assigned to receive either KEYTRUDA at a flat dose of 200 mg intravenously on day 1 of each 21-day cycle for up to 1 year or placebo IV on day 1 of each 21-day cycle for up to 1 year.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Swiss drug major Roche Holding AG reported Wednesday higher sales in its first nine months of fiscal 2018, with growth in Pharmaceuticals sales in all regions except Europe. Diagnostics Division also recorded higher sales in all regions. Looking ahead to fiscal 2018, Roche confirmed its outlook for higher results at constant exchange rates. Online-video streaming service Netflix Inc. (NFLX), Tuesday reported a third-quarter profit that surged from last year as revenues increased 34% driven largely by strong subscriber additions. Shares surged nearly 12 percent in the after-hours trading. Netflix added 6.96 million subscribers globally... Despite opposition from the pharmaceutical industry, President Donald Trump's administration has proposed a new rule requiring companies to include the prices for prescription drug and biological products in their television advertisements.
Follow RTT